id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-285533-f1fonmo6	Zeng, Jia	Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients	2020-09-06		.txt	text/plain	2885	152	44	The Diagnosis and Treatment Guidelines of New Coronavirus Pneumonia (7(th) Edition) includes tocilizumab as a recommended drug for immunotherapy in severe and critical COVID-19 patients. Some studies [3] [4] [5] have found that the main pathophysiological basis of COVID-19 causing respiratory failure and even hypoxic death, is immune cells released by mononuclear/macrophage cells after infection with the new coronavirus (SARS-CoV-2) in the blood which further activate the body's immune cells (such as monocytes, macrophages, T cells, B cells, etc.) or non-immune cells (such as endothelial cells), causing these cells to release a large number of cytokines (cytokine storm), thereby seriously destroying the ventilation function of lungs. The Diagnosis and Treatment Guidelines of New Coronavirus Pneumonia (7 th Edition) includes tocilizumab as a recommended drug for immunotherapy in patients with severe COVID-19 [6, 7] . The results showed that after tocilizumab treatment, the lymphocyte count and oxygenation index of the improved patients increased significantly, while CRP and FIB showed an overall downward trend.	./cache/cord-285533-f1fonmo6.txt	./txt/cord-285533-f1fonmo6.txt